Navigation Links
EquitiesIQ Initiates Coverage of Alliqua, Inc.
Date:1/14/2014

New York, NY (PRWEB) January 14, 2014

EquitiesIQ, a leading informational research provider, has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, developing, manufacturing, and marketing proprietary products to serve the wound care market.

Free report download: http://equitiesiq.com/reports/alliqua/

In late 2012, Alliqua was restructured with a seasoned management team and Board, which launched the company’s new strategy to become a leading provider of wound care products. Coincident with the new leadership, Alliqua raised capital from company insiders along with a group of retail and institutional investors. With this initial capital, Alliqua began to build its sales infrastructure and consolidate its operations.

Throughout 2013, the company entered strategic relationships with a variety of wholesale distributors including Team Distribution International, World Health Industries, McKesson Medical-Surgical, and Medline. Alliqua also secured a license agreement with sorbion GmbH & Co. to distribute wound care dressings based on sorbion’s proprietary hydroactive technology.

In November 2013, the company entered into an agreement with Celgene Corporation (CELG) to develop and market wound healing products based on Celgene Cellular Thereapeutics’ (CCT) placenta-derived technology. Products based on this technology are anticipated to have superior wound-healing characteristics, and will enable Alliqua to enter one of the fastest growing segments of the wound care market. In conjunction with the Celgene license agreement, a group of healthcare-focused institutional investors, and Celgene itself, collectively made a $14 million equity investment into the company.

Well capitalized, with its own line of value-added hydrogels, the sorbion wound care dressings, and the tissue based wound healing products from Celgene, Alliqua is now positioned to address a spectrum of wounds with a broad line of innovative solutions.

The full Initiation Report is available to download at the EquitiesIQ website. EquitiesIQ will provide ongoing coverage and event-based updates as developments occur.

Free report download: http://equitiesiq.com/reports/alliqua/

About EquitiesIQ

EquitiesIQ publishes and distributes research reports that enhance the visibility of our client companies. Our reports are written by analysts who recognize investors’ desire to understand a business in a way that supports an educated investment decision. To learn more about EquitiesIQ, visit the company's website, http://equitiesiq.com. EquitiesIQ is not a registered investment adviser or broker-dealer.

Important Disclosures and Disclaimers

The research report described in this press release has been prepared by EquitiesIQ, LLC on behalf of Alliqua, Inc. (the “Company”), as part of investor relations services provided to Alliqua by EquitiesIQ. EquitiesIQ has been compensated for preparation of the research report and for future coverage, as fully disclosed in the report. David Moskowitz is the author of the report and the views regarding Alliqua expressed in the report accurately reflect the personal views of Mr. Moskowitz regarding Alliqua and its securities, as of the date of the report.

The research report is not an offer or solicitation to buy or sell the securities of the Alliqua. This report is for information purposes only, and is not intended to (and is provided explicitly on the condition that it not) be used as the sole basis to make any investment decision. Investors should make their own determinations whether an investment in any particular security is consistent with their investment objectives, risk tolerance, and financial situation. EquitiesIQ and its affiliates are not recommending any investments based on the information in the research report.

Forward-looking Statements

This press release and the research report contain forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. EquitiesIQ does not guarantee the accuracy and comprehensiveness of these predictions. You should not invest in the Alliqua in reliance on these forward-looking statements.

Please read the full disclosures and disclaimers at the end of the report as well as the general disclaimers and terms at http://equitiesiq.com/disclaimer.

Read the full story at http://www.prweb.com/releases/2014/01/prweb11485599.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
2. Baxter Initiates Phase I Clinical Trial of Longer-acting Recombinant FVIII Treatment for Hemophilia A
3. Research Alert -- Empire Asset Management Co. Initiates Coverage on Exact Sciences (NASDAQ: EXAS)
4. Applied Genetics Initiates Commercial Operation
5. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare
6. Medbox, Inc. Initiates "Responsible Consumption" Campaign for Marijuana in Recreational States
7. Shire Regenerative Medicine Initiates Phase 3 Study of ABH001 for Patients with Epidermolysis Bullosa
8. ADVENTRX Initiates Thorough QT/QTc Clinical Study Of ANX-188
9. Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
10. NewLink Genetics Initiates Phase 2 Trial of IDO Pathway Inhibitor, Indoximod, for the Treatment of Metastatic Breast Cancer
11. MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... PRUSSIA, PA (PRWEB) , ... December 01, 2016 , ... ... is through industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were ... more than 100 clinical trial leaders from over 40 sponsor, CRO and site organizations ...
(Date:12/2/2016)... Dec. 1, 2016   SurePure, Inc. (OTCQB: ... that the Company has concluded an agreement with Tamarack ... a 90-day period to acquire units of the Company,s ... USD 3.7 million.  Concurrently with the ... under which Tamarack will seek regulatory approvals in ...
(Date:11/30/2016)... 30, 2016  GenomOncology today announced the appointment of ... Affairs.  Dr. Coleman will oversee clinical content ... knowledge-enabled platform. The GenomOncology software suite empowers molecular pathologists with ... and clinical decision support, from quality control through reporting. ... , , ...
(Date:11/30/2016)... , Nov. 30, 2016  The Allen Institute ... Collection: the first publicly available collection of gene ... that target key cellular structures with unprecedented clarity. ... these powerful tools are a crucial first step ... better understand what makes human cells healthy and ...
Breaking Biology Technology:
(Date:6/21/2016)... 21, 2016 NuData Security announced today that ... of principal product architect and that Jon ... customer development. Both will report directly to ... moves reflect NuData,s strategic growth in its product ... customer demand and customer focus values. ...
(Date:6/9/2016)... -- Perkotek an innovation leader in attendance control systems is proud to announce the introduction ... to make sure the right employees are actually signing in, and to even control ... ... ... ...
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
Breaking Biology News(10 mins):